Johnson & Johnson Unveils Rebranding of Five Core MedTech Subsidiaries Under Unified Johnson & Johnson MedTech Identity

Sep 12, 2024 17:51 CST Updated 17:51

Johnson & Johnson

Medical Device R&D and Manufacturer

Johnson & Johnson is simplifying and reshaping its brand.

Recently, Johnson & Johnson, a global healthcare giant, announced that it would integrate its five medical device businesses under the name of Johnson & Johnson Medical Technologies. Ethicon, Depuy Synthes, Biosense Webster, Abiomed, and Cerenovus will no longer exist as independent entities; however, Johnson & Johnson stated that its product portfolio remains unchanged. From now on, these businesses will operate under the Johnson & Johnson Medical Technologies brand name. This move is part of the next step in the brand and visual identity update announced by Johnson & Johnson last fall. These changes will not affect the current medical technology products and solutions provided to customers.

A Century-Old Brand, Rejuvenated

On September 14, 2023, Johnson & Johnson announced a brand refresh, replacing its 135-year-old logo with a newly designed emblem. The company will emphasize the abbreviated brand identifier "J&J" in digital interfaces and other application scenarios. At the same time, it announced the integration of its two businesses, medical technology and pharmaceuticals, under the Johnson & Johnson name to establish a closer connection between these two segments and the Johnson & Johnson brand. The pharmaceutical business, Janssen, will be renamed Johnson & Johnson Innovative Medicine, while Johnson & Johnson MedTech will remain unchanged.

This time, integrating all five sub-brands under the Johnson & Johnson Medical Technology brand will further enhance its core competitiveness.

Tim Schmid, Executive Vice President and Global Chair of Johnson & Johnson MedTech, commented: "Johnson & Johnson is addressing some unmet clinical needs in healthcare through innovative pharmaceuticals and medical technologies. By integrating our MedTech business under the Johnson & Johnson umbrella, our impact in the healthcare field will become even more prominent, creating new opportunities to enhance our competitiveness. While Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Cerenovus will now be renamed as Johnson & Johnson MedTech, we will continue to honor the legacy of these brands, maintaining their products, services, and collaborative approaches, which have made them among the most trusted names in medicine."

Johnson & Johnson stated that partners, customers, and consumers will begin to see the changes in brand transformation on social media channels and marketing materials in the coming weeks. The updated brand and visual identity will not impact the company’s product portfolio.

Ethicon

In 1944, Ethicon was established as a subsidiary of Johnson & Johnson. It is a division under Johnson & Johnson Medical Technologies that focuses on surgical solutions, specializing in the development of innovative laparoscopic and minimally invasive surgical products. These include products for cardiovascular surgery, general surgery, breast surgery, plastic surgery, spinal surgery, wound closure, and ligation. As part of Johnson & Johnson Medical Devices, Ethicon has made significant contributions to surgical procedures over more than 100 years, from creating the first sutures to revolutionizing surgery with minimally invasive techniques.

After World War II, the market share of Johnson & Johnson's Ethicon suture products increased from 15% to over 70% globally, and exceeded 80% in the U.S. market, making it the world’s most comprehensive suture manufacturer. In 1982, Johnson & Johnson established an operational office in Beijing, officially entering the Chinese market with its suture products. In 1995, Johnson & Johnson's Ethicon acquired Mitek Surgical Products, the world's leading company in sports trauma, expanding its product range into the orthopedic field.

Depuy Synthes

DePuy Synthes is a globally leading orthopedics and neurosurgery company, with a history that dates back to the late 19th century. Evidence shows that DePuy Manufacturing Company was initially founded in the 1890s by a traveling salesman in Indiana, originally producing fiber splints for fracture immobilization. After 125 years of development, the company has become part of Johnson & Johnson and grown into one of the world’s leading orthopedic businesses.

In 2011, Johnson & Johnson acquired another orthopedic giant, Synthes, for $21.3 billion, integrating it into its DePuy subsidiary, thereby creating the world's most comprehensive orthopedic and neurological company. This merger enabled DePuy Synthes to possess a broader portfolio of orthopedic products, including joint reconstruction, trauma care, spinal surgery, sports medicine, craniomaxillofacial surgery, as well as power tools and biomaterials.

Currently, the main products of DePuy Synthes cover multiple specialized fields, such as hip replacement, knee replacement, shoulder replacement, and spinal repair. In addition, the company is committed to advancing orthopedic surgery through innovative technologies like the VELYS Digital Surgery solution. These innovations not only improve surgical efficiency but also provide patients with more personalized treatment options. In the latest global top ten orthopedics ranking, Johnson & Johnson's DePuy Synthes ranked first.

Biosense Webste

Biosense Webster is a globally leading company specializing in the field of cardiac electrophysiology. Established in 1970 by Will Webster, Jr., the company has deep technical expertise in cardiac electrophysiology and continuously introduces innovative products.

In 1996, Johnson & Johnson acquired Cordis and Biosense Webster for $1.8 billion and $400 million respectively, officially entering the cardiac electrophysiology industry. This move made Biosense Webster an important subsidiary of Johnson & Johnson, responsible for its electrophysiology business.

Since being acquired by Johnson & Johnson, Biosense Webster has rapidly developed and taken a dominant position in the global cardiac electrophysiology market. By 2015, the company had captured 40% of the global cardiac electrophysiology market share. In addition, Biosense Webster launched the world's first 3D cardiac electrophysiology mapping system, the CARTO system, and has continued to iterate and innovate its technology.

In recent years, Biosense Webster has continued to advance technological innovation, such as introducing artificial intelligence into its electrocardiogram mapping system, CARTO 3. In addition, the company is also developing pulsed field ablation technology for the treatment of conditions like atrial fibrillation.

Abiomed

Abiomed was founded in 1981 by David M. Lederman in Danvers, Massachusetts. The company's initial goal was to develop the world's first artificial heart and focus on research and innovation in cardiac recovery technologies. During its early stages of development (1981-2000), Abiomed concentrated on the research, development, and production of implantable ventricular assist devices (VADs), launching product lines such as the BVS5000 and ABS5000. However, the revenue performance of these products was modest. It wasn’t until 2005 that Abiomed began its transformation and expanded its business scope by acquiring a company from Germany.

Since 2004, Abiomed has undergone three significant mergers and acquisitions along with strategic transformations, gradually establishing its leading position in the global cardiovascular medical device industry. Among these, the Impella series of heart pumps have become the company's core product, known as "the world's smallest heart pump," used for supportive treatment of diseases such as heart disease and heart failure. In the fiscal year 2021, the sales revenue of the Impella series reached $806 million, accounting for over 95% of the company’s total revenue.

In November 2022, Johnson & Johnson acquired Abiomed for $16.6 billion, making it part of Johnson & Johnson Medical Technologies. This move not only solidified Johnson & Johnson's position in the cardiovascular device market but also means that Abiomed will benefit from Johnson & Johnson's strong market presence, with the potential to further promote its Impella products globally.

Cerenovus

Cerenovus is an emerging leader in the neurovascular care sector under Johnson & Johnson Medical Technologies, focusing on providing solutions for ischemic and hemorrhagic strokes. The company was established in 2017 based on the acquisitions of Pulsar Vascular, a manufacturer of devices for brain aneurysms, and Neuravi, a developer of neurovascular treatment technologies.

Cerenovus offers a wide range of devices used in endovascular treatments, including the CereGlide 71 Intermediate Catheter for revascularization in patients with acute ischemic stroke, and the next-generation TRUFILL™ n-BCA Liquid Embolic System for hemorrhagic stroke. These products demonstrate the company's innovative capabilities and technical expertise in the field of neurovascular care.

Challenges and Opportunities Coexist, Johnson & Johnson Accelerates Transformation

As Johnson & Johnson further strengthens its brand core competitiveness, it also reflects the company’s determination to address market challenges and undergo strategic transformation. However, Johnson & Johnson currently faces multiple pressures, including management instability caused by frequent senior-level personnel changes, the impact of financial strain and layoffs on employee morale, coordination issues during the brand renewal and business integration process, as well as competition in the market and the broader macroeconomic environment.

Personnel Changes

In recent years, Johnson & Johnson has experienced frequent personnel changes across multiple business units, especially in the China market, which has seen a series of leadership transitions. These include the resignation of Chen Chuhui, General Manager of the Cardiovascular and Specialty Solutions division, and the replacement of the President of the China region. These high-level changes reflect the need for strategic adjustments within the company, but the turnover has also introduced some instability to the business.

Layoffs

Johnson & Johnson Conducted Large-Scale Layoffs in 2024, Kenvue Globally Cut Approximately 920 Jobs

Acquisition

On April 5, 2024, Johnson & Johnson and Shockwave Medical announced a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Shockwave for $335 per share in cash. The total value of the transaction is approximately $13.1 billion, including the acquisition cash. The transaction has been approved by the boards of both companies. On August 20, 2024, Johnson & Johnson announced that it had completed the ultimate merger agreement with V-Wave, a leader in cardiovascular devices. Through a series of acquisitions, Johnson & Johnson has demonstrated its determination to further expand its market share in the cardiovascular field. The company has stated that there are significant market opportunities in this largely unmet area.

With the rapid development of the healthcare industry, Johnson & Johnson faces fierce competition in the global market. Emerging medical technologies and products are constantly emerging, and Johnson & Johnson needs to continuously innovate and improve product quality to maintain its market position. Meanwhile, Johnson & Johnson always maintains sharp insight, closely follows the changing international economic landscape, and flexibly adjusts its strategic direction to embrace every challenge and opportunity in the best possible way.

▲Source of the article:Medical Device Innovation Network

▲Reproduction without permission is prohibited.And can be reprinted after 24 hours.！

Disclaimer: This article is intended solely for the purpose of information transmission and is for reference only. It does not constitute any advice on investment or treatment; please evaluate carefully. If it involves the content, copyright, or other issues of the work, to protect the rights and interests of both parties, please contact us and we will handle it immediately. If any platform reprints this article, it must take responsibility for the article itself; the Medical Device Innovation Network is not responsible for any secondary dissemination caused by the reprint.

PREVIOUS REVIEW

R&D Investment Competition Among Top Medical Device Companies in China and Abroad: Johnson & Johnson, Medtronic, Mindray... Who Takes the Lead?

More Than 14,000 Layoffs in Half a Year: Has the Medical Device Sector Emerged from the "Winter"?

Revenue of 14.6 Billion, 341 Units Installed! da Vinci Q2 Wows Wall Street